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Available online 2 June 2016Purpose: This report sheds light on a successful treatment in febrile infection-related epilepsy syndrome (FIRES)
with the combined use of lidocaine and MgSO4.
Methods:We report a 12-year-old previously healthy girl who experienced an upper respiratory infection with
fever and headache for 2 days, then suddenly went into a coma followed by repetitive status epilepticus. All
tests for CNS infection, metabolic and toxic diseases, and autoimmune encephalitis were negative. Hence, the di-
agnosis of FIRES wasmade. During 5 weeks of hospital treatment, various antiepileptic drugs were administered
at different times without success. To achieve seizure control, we then attempted the use of lidocaine ﬁrst, then
followed by MgSO4.
Results: The SE was successfully controlled when lidocaine plus MgSO4 was introduced. At follow-up, almost no
neurological sequelae remained.
Conclusion: This is the ﬁrst report describing the combined use of lidocaine andMgSO4with successful treatment
outcomes. This experience has indicated that even FIRES can be controlled if treated promptly with certain
agents. However, more studies are needed to explore the mechanisms and effects of lidocaine and MgSO4 in
FIRES.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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MgSO41. Introduction
Febrile infection-related epilepsy syndrome (FIRES), also known as
devastating epileptic encephalopathy in school-aged children or acute
encephalitis with refractory repetitive partial seizures, is an acute and
explosive-onset epileptic encephalopathy with a fatal outcome, which
occurs in previously healthy children following a nonspeciﬁc febrile ill-
ness [1,2]. The precise etiology of this syndrome and the effective treat-
ment options remain unclear. Herein, we present our experience in
treating a 12-year-old girl with FIRES, who dramatically recovered
from this devastating encephalitis after treatment with a combination
of lidocaine and MgSO4.trics, China Medical University
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A 12-year-old girl was admitted to our emergency department with
complaints of severe headache, dizziness, and fever (38 °C). Prior to her
admission, she was healthy without any epileptic disorders and had
normal development. The patient did not have a familial history of
any epileptic or genetic metabolic disease. A week prior to admission,
she experienced fever, sore throat, and fatigue and was treated for
acute pharyngitis. On admission, she had a Glasgow Coma Scale (GCS)
score of 12. On Day 2 of admission, her condition worsened rapidly,
and she fell into a state of coma (GCS score of 3). She then manifested
intractable status epilepticus (SE) with generalized tonic–clonic sei-
zures, accompanied by tachycardia, respiratory compromise, and hypo-
tension alternating with myoclonic jerks of both lower limbs. Although
SEwas temporarily stabilized by administration of BZD agents, the focal
myoclonic seizures, involving both lower limbs alternatively, did not
stop. Interictal electroencephalography (EEG) revealed diffuse slow
delta activity (Fig. 1), distributed with frequent bouts of ictal fast activ-
ity. Initially, central nervous system infectionwas highly suspected, and
sowe initiated antibiotic and antiviral treatments; however, thesewerethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. (A) On Day 1 of admission, the patient was in a state of deep coma; electroencephalography (EEG) background consisted of slow delta waves (3–4 Hz, 25–50 μV). (B) On Day 2, the
EEG pattern shifted to a slow backgroundmixedwith numerous spikes or sharp-wave activity from both hemispheres. (C and D) On Day 3, 8–9 s before the generalized seizure occurred,
the EEG pattern in the right frontal–temporal region transformed into fast low-voltage activities (C) and quickly entered a state of generalized fast low-voltage activities. In the clinical
setting, generalized tonic–clonic seizure appeared (D). (E) On Day 31 of admission (3 days of lidocaine use prior to the introduction of MgSO4), the EEG background consisted of a
slow theta wave (4–5 Hz, 25–50 μV) interspersed with paroxysmal spike activities. (F) On Day 35, after the introduction of lidocaine for 7 days and MgSO4 for 4 days, neither clinical
seizures nor epileptiform activities on EEG were noted.
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croarray, high-throughput sequencing, and molecular biological
detection to detect encephalitis with unknown pathogens based on
Taiwan Pathogenic Microorganism Genome Database were performed,
but all test results were negative.
Unrevealing laboratory investigations included arterial blood gas
analysis; complete blood count; blood glucose level; electrolyte panel;
serum concentrations of blood urea nitrogen, creatinine, calcium,
magnesium, phosphate, and liver enzymes (aspartate aminotransferase,
alanine transaminase, coagulation studies, and serum concentrations of
bilirubin and ammonia); and cultures of blood and cerebrospinal ﬂuid.
Specialized metabolic tests were also conducted including quantitative
plasma amino acids, evaluation of plasma lactate and pyruvate levels,
acylcarnitine proﬁle, and qualitative urine organic acids. Drug testing
using appropriate panels was performed on samples of blood and
urine to determine the presence of drugs that can cause altered levels
of consciousness, such as sedatives, salicylates, hallucinogenic agents,
anticholinergic agents, opioids,monoamineoxidase inhibitors, acetamino-
phen, selective serotonin reuptake inhibitors, and tricyclic antidepressants
and was negative. In addition, we examined for the presence of environ-
mental toxins, such as organophosphates, lead or other heavy metals,
and hydrocarbons in the aforementioned biological samples — all wereunremarkable. Screening for autoimmune and paraneoplastic panel in
blood or cerebrospinal ﬂuid [i.e., antibodies of anti-Hu, anti-Yo, anti-Ri
(ANNA2), anti-MA2 (Ma2/Ta), anti-CV2/CRMP5, antiamphiphysin, anti-
NMDAR, anti-Caspr2, anti-AMPAR, anti-LGI1] revealed negative results.
Based on these test results, a diagnosis of FIRES was made.
Status epilepticus (SE) was treated using various drugs at different
time points, speciﬁcally using phenobarbital (PHB; 15 mg/kg for load-
ing, 3 mg/kg/day for maintenance), phenytoin (15 mg/kg for loading,
5 mg/kg/day for maintenance), valproic acid (15 mg/kg/day gradually
titrated to 60mg/kg/day), levetiracetam (LEV, 1500mgq12hr), intrave-
nous immunoglobulin (1 g/kg; up to 3 courses), dexamethasone
(7 days), midazolam (20 mg/kg/min continuous intravenous infusion),
pyridoxine, and a ketogenic diet (stopped by gastrointestinal bleeding).
The levels of all these drugs were closely monitored to ensure their ef-
fectiveness. However, SE occurred up to dozens of times a day (N30
times overall; Fig. 2).
Drug-induced comas were induced four times (two times with
pentobarbital, one time with propofol, and one time with thiopen-
tal). Throughout the course of hospital admission, frequent EEG
monitoring was performed. Electroencephalography showed burst-
suppression features with suppression periods lasting 4–5 s and
without electroclinical seizures. However, every time the dose of
Fig. 2. Timeline of clinically observed seizures and treatment with various intravenous-
type AEDs. AEDs = antiepileptic drugs; GTCs = generalized tonic–clonic seizures;
PBT = pentobarbital; PHB = phenobarbital; PHT = phenytoin; PROP = propofol;
VPA = valproic acid.
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resonance imaging was performed two times, which demonstrated
abnormal hyperintensities bilaterally over the external capsules, medial
temporal lobes, hippocampi, and posteromedial thalami (Fig. 3).
On Day 27 of admission, we started lidocaine therapy at a dose of
1.25 mg/kg/h. Over the next 2 days, the severity and frequency of her
generalized-type SE were reduced a third. On Day 30, we added
MgSO4 at a dose of 20 mg/kg/h, which markedly improved the SE
and EEG readings from Day 1 of administration (Fig. 2); her blood
magnesium level was 3.3 mg/dL the next day. Therefore, we
discontinued the barbiturate-induced coma and gradually lowered
the dose of midazolam infusion over several days before stopping it
completely. She was discharged from the intensive care unit (ICU)
with intravenous lidocaine, MgSO4, and LEV. At this time, no clinical
seizure had been noted.
An overview of the patient's seizure evolution is as follows: the ictal
discharge in the right frontal–temporal region along with left-sided
tonic seizure started approximately 8–10 s before the generalized sei-
zure occurred, and when this was stopped by administering an anes-
thetic or BZD, the seizure transformed into clinical myoclonic jerks of
both lower limbs (L N R) with EEG slow wave with/without visible epi-
leptiform discharges. Fig. 1 shows the EEG tracings obtained at different
time points.
She then received rehabilitation therapy to counteract the prolonged
period during which she had been bedridden in the ICU. Gradually, she
could walk stably, write smoothly, and respond ﬂuently. She wasFig. 3. (A) Initial magnetic resonance imaging (MRI) images: T2-weighted (T2W) ﬂuid-attenuat
edema and hyperintensities of the bilateral external capsules andmedial temporal lobes alongw
FLAIR images (taken onDay 21 of admission) showingmild remission of abnormal cortical swel
capsules (arrow).discharged after 39 days of admission. Although seizures did not occur
when all intravenous-type antiepileptic drugs (AEDs) were stopped,
the discharge medication was a prophylactic polytherapy with PB,
LEV, topiramate, lorazepam, and pyridoxine. Twoweeks after discharge,
she returned for neurological and neuropsychological follow-up. Nei-
ther seizures nor signiﬁcant neurological complications were observed
during this period; however, her short-term memory was slightly im-
paired "by amnesia". Neuropsychological evaluation with the Wechsler
Intelligence Scale for Children—IV revealed no difference in the four factor
indices compared with expected values for her age.
3. Discussion
To most neurologists, treating FIRES is extremely problematic
because its etiology and treatment remain unclear. Although the severe
seizures can be controlled, the patient is usually left with a grave psy-
chomotor impairment. In this case, we not only found that a combined
regimen of lidocaine and MgSO4 achieved a favorable control of SE but
also found that it resulted in minimal psychomotor impairment.
With the exceptions of comas induced by anesthetics or barbitu-
rates, most AEDs fail to stop the SE that results from FIRES. However,
the signiﬁcant danger is that the longer the burst-suppression coma is
induced, the worse the cognitive outcome [3]. A review of the
literature showed that few regimens have been proposed for this condi-
tion. Capizzi et al. [4] used lidocaine treatment and eventually con-
trolled the refractory SE after 9 weeks of numerous ineffective AED
treatments. Lin et al. [5] reported that moderate therapeutic hypother-
mia at 33 °C resulted in a sustained control of refractory SE. In another
study on 12 patients with FIRES [6], immunoglobulin and a ketogenic
diet were demonstrated to be a potentially efﬁcacious treatment.
In the present case, three courses of intravenous immunoglobulin
(1 g/kg) were administered but were ineffective. The presence of volu-
minous amounts of coffee grounds and gastric juices in the nasogastric
tubemade it difﬁcult to implement the ketogenic diet. After administer-
ing lidocaine for 2 days, the frequency of generalized seizures reduced
to one-third, but when MgSO4 was added, the number of seizures
dropped markedly to no more than three per day within 3 days. After
3 days, the patient was seizure-free.
The mechanism that caused lidocaine and MgSO4 to apparently
work in our case is unclear. Capizzi et al. [4] assumed that lidocaine,
being a local anesthetic drug as well as an antiarrhythmic drug (Class
IB), has membrane-stabilizing effects and exhibits a central local anes-
thetic action on the inhibitory pathway ﬁbers involved in direct cortical
stimulation [4]. At present, lidocainehas beenwidely used in the controled inversion recovery (FLAIR) images (taken onDay 3 of admission) showing symmetrical
ith the hippocampi and posteromedial thalami (arrow). (B) Follow-upMRI images: T2W
ling in the bilateralmedial temporal lobes, hippocampi, thalami, basal ganglia, and external
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used in eclampsia but rarely in FIRES, is a seizure prophylactic; itsmech-
anism of action, however, remains unclear [8]. Zeiler et al. [9] reviewed
19 original articles and suggested a trend toward improved seizure con-
trol with the use of intravenous MgSO4 for noneclamptic refractory SE
[9]. One hypothesis is that severe preeclampsia is a state of increased
seizure susceptibility resulting from blood–brain barrier disruption
and neuroinﬂammation, which lowers the seizure threshold [10]. Fur-
ther, MgSO4 decreases seizure susceptibility by protecting the blood–
brain barrier and preventing neuroinﬂammation. Although the patho-
physiology of FIRES is undetermined, the mechanism that caused the
combination of lidocaine and MgSO4 to apparently work successfully
in our case provides a clue for FIRES research and understanding.
4. Conclusion
This is the ﬁrst report describing the combined use of lidocaine and
MgSO4 with successful treatment outcomes. This experience provided a
different treatment option for control of status epilepticus due to FIRES
when all conventional AEDs failed. However, more studies are needed
to explore themechanisms and effects of lidocaine andMgSO4 in FIRES.
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